Rock Tech Lithium Valuation
Is RJIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RJIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RJIB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RJIB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RJIB?
Key metric: As RJIB is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is RJIB's PB Ratio? | |
|---|---|
| PB Ratio | 3.2x |
| Book | CA$33.14m |
| Market Cap | CA$107.22m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -5.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does RJIB's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.2x | ||
M0LY Greenland Resources | 45.3x | n/a | €69.4m |
W2C IberAmerican Lithium | 27.6x | n/a | €821.3k |
PNX Pasinex Resources | 35.8x | n/a | €1.4m |
BNN BRAIN Biotech | 4.3x | 71.5% | €69.9m |
RJIB Rock Tech Lithium | 3.2x | -61.0% | €107.2m |
Price-To-Book vs Peers: RJIB is good value based on its Price-To-Book Ratio (3.2x) compared to the peer average (24.2x).
Price to Book Ratio vs Industry
How does RJIB's PB Ratio compare vs other companies in the European Metals and Mining Industry?
| 23 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: RJIB is expensive based on its Price-To-Book Ratio (3.2x) compared to the European Metals and Mining industry average (0.9x).
Price to Book Ratio vs Fair Ratio
What is RJIB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate RJIB's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.72 | €1.38 +91.6% | 38.4% | €1.93 | €0.67 | n/a | 3 |
| Nov ’25 | €0.81 | €1.38 +70.1% | 38.4% | €1.93 | €0.67 | n/a | 3 |
| Oct ’25 | €0.81 | €1.37 +69.0% | 38.4% | €1.92 | €0.66 | n/a | 3 |
| Sep ’25 | €0.79 | €1.41 +78.1% | 38.4% | €1.98 | €0.68 | n/a | 3 |
| Aug ’25 | €0.92 | €1.41 +53.4% | 38.4% | €1.98 | €0.68 | n/a | 3 |
| Jul ’25 | €1.12 | €1.41 +25.9% | 38.4% | €1.98 | €0.68 | n/a | 3 |
| Jun ’25 | €0.93 | €1.40 +50.5% | 38.4% | €1.96 | €0.68 | n/a | 3 |
| May ’25 | €0.84 | €1.45 +72.0% | 38.3% | €1.97 | €0.68 | n/a | 3 |
| Apr ’25 | €0.79 | €1.79 +127.0% | 41.3% | €2.75 | €0.69 | n/a | 4 |
| Mar ’25 | €0.77 | €1.79 +132.0% | 41.3% | €2.75 | €0.69 | n/a | 4 |
| Feb ’25 | €0.79 | €1.79 +126.4% | 41.3% | €2.75 | €0.69 | n/a | 4 |
| Jan ’25 | €0.92 | €1.74 +89.4% | 41.3% | €2.68 | €0.67 | n/a | 4 |
| Dec ’24 | €0.86 | €1.74 +102.9% | 41.3% | €2.68 | €0.67 | n/a | 4 |
| Nov ’24 | €0.77 | €2.50 +222.8% | 56.0% | €4.09 | €0.68 | €0.81 | 3 |
| Oct ’24 | €1.05 | €2.69 +157.1% | 33.7% | €4.12 | €1.72 | €0.81 | 4 |
| Sep ’24 | €1.31 | €3.73 +184.6% | 41.3% | €5.42 | €1.69 | €0.79 | 3 |
| Aug ’24 | €1.37 | €3.73 +171.3% | 41.3% | €5.42 | €1.69 | €0.92 | 3 |
| Jul ’24 | €1.42 | €3.73 +162.2% | 41.3% | €5.42 | €1.69 | €1.12 | 3 |
| Jun ’24 | €1.59 | €3.73 +134.5% | 41.3% | €5.42 | €1.69 | €0.93 | 3 |
| May ’24 | €1.56 | €3.81 +144.9% | 38.7% | €5.47 | €1.88 | €0.84 | 3 |
| Apr ’24 | €1.85 | €4.24 +129.7% | 47.4% | €6.78 | €1.87 | €0.79 | 3 |
| Mar ’24 | €1.83 | €5.42 +197.0% | 37.9% | €7.39 | €2.59 | €0.77 | 3 |
| Feb ’24 | €2.10 | €5.42 +158.2% | 37.9% | €7.39 | €2.59 | €0.79 | 3 |
| Jan ’24 | €1.53 | €5.42 +253.5% | 37.9% | €7.39 | €2.59 | €0.92 | 3 |
| Dec ’23 | €2.00 | €5.42 +171.1% | 37.9% | €7.39 | €2.59 | €0.86 | 3 |
| Nov ’23 | €2.55 | €5.86 +129.8% | 30.3% | €7.64 | €3.44 | €0.77 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
UBE
JP¥241.7b
Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.
UBE
JP¥15.30
7D
8.5%
1Y
7.7%
Tokuyama
JP¥197.6b
Produces and sells various chemical products in Japan.
TBT
JP¥16.70
7D
5.0%
1Y
16.0%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.27
7D
2.9%
1Y
-8.1%